Asthma Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Asthma Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Asthma is a long-term inflammatory disease that causes inflammation and narrowing of the airways in the lung. It is characterized by various symptoms such as swelling or inflammation in the airways linings, coughing, shortness of breath, and tightness of chest. Asthma is classified into many different types including allergic asthma, non-allergic asthma, adult onset asthma, exercised induced asthma (that occurs with physical exertion), nocturnal asthma, and occupational asthma. Nocturnal is also known as the nighttime asthma. It is very serious type of asthma therefore, it needs a proper diagnosis and treatment.
Market Dynamics
Increasing launches of nebulizer by key players is expected to propel global asthma therapeutics market growth. For instance, in October 2018, Koninklijke Philips N.V. announced launch of its new mesh nebulizer, InnoSpire Go, in North America. This is used for the treatment of respiratory diseases including asthma. It is portable, hand-held nebulizer system, which is short time treatment. It delivers the medicine in just four minutes. InnoSpire Go designed for both adults and children.
However, product recall is major restraining factor for asthma therapeutics market growth, which is expected to hamper the market growth. For instance, in August 2018, Camber Pharmaceuticals were issued product recall alert from U.S. Food and Drug Administration for its Montelukast Sodium Tablets. These tablets are recalled because Montelukast Sodium Tablet bottles contain wrong medicine (Losartan Potassium Tablet).
Key features of the study:
This report provides in-depth analysis of the global asthma therapeutics market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global asthma therapeutics market based on the following parameters–company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global asthma therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for global asthma therapeutics market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Asthma Therapeutics Market, By Drug Class:
Corticosteroids
Beta2-Agonists (Long-Acting and Short-Acting)
Leukotriene Inhibitors
Long-Acting Muscarinic Antagonists (LAMA)
Interleukin Antagonists
Anti-Immunoglobulin E (IgE) Agents
Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
Others
Global Asthma Therapeutics By Route of Administration:
Oral
Inhalation
Injection
Global Asthma Therapeutics market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Asthma Therapeutics market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class
Corticosteroids
Beta2-Agonists (Long-Acting and Short-Acting)
Leukotriene Inhibitors
Long-Acting Muscarinic Antagonists (LAMA)
Interleukin Antagonists
Anti-Immunoglobulin E (IgE) Agents
Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class
Corticosteroids
Beta2-Agonists (Long-Acting and Short-Acting)
Leukotriene Inhibitors
Long-Acting Muscarinic Antagonists (LAMA)
Interleukin Antagonists
Anti-Immunoglobulin E (IgE) Agents
Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class
Corticosteroids
Beta2-Agonists (Long-Acting and Short-Acting)
Leukotriene Inhibitors
Long-Acting Muscarinic Antagonists (LAMA)
Interleukin Antagonists
Anti-Immunoglobulin E (IgE) Agents
Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class
Corticosteroids
Beta2-Agonists (Long-Acting and Short-Acting)
Leukotriene Inhibitors
Long-Acting Muscarinic Antagonists (LAMA)
Interleukin Antagonists
Anti-Immunoglobulin E (IgE) Agents
Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class
Corticosteroids
Beta2-Agonists (Long-Acting and Short-Acting)
Leukotriene Inhibitors
Long-Acting Muscarinic Antagonists (LAMA)
Interleukin Antagonists
Anti-Immunoglobulin E (IgE) Agents
Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Class
Corticosteroids
Beta2-Agonists (Long-Acting and Short-Acting)
Leukotriene Inhibitors
Long-Acting Muscarinic Antagonists (LAMA)
Interleukin Antagonists
Anti-Immunoglobulin E (IgE) Agents
Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
GlaxoSmithKline Plc.,*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Philips Healthcare
AstraZeneca Plc.
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim GmbH
Sanofi-Aventis SA
CareFusion Corporation
Sunovion Pharmaceuticals, Inc.
Merck & Co., Inc.
Roche Diagnostics.
“*” marked represents similar segmentation in other categories in the respective section.